“Again, the safety and efficacy (even if slightly lower than expected) should earn LL an EUA and Phase 4. Unconscionable to do it any other way.”

Here’s my question: what did the various FDAs say to CYDY about the data? They responded because NP told us that the data would be released AFTER talks concluded. Obviously they didn’t offer an EUA or we would’ve got that PR, but maybe they’re asking for a few more patients, etc. Hard to say until the CC as the PR didn’t discuss the path forward after the discussions.